HM1 Says Revaluation of Opthea's Holding Value to Negatively Impact NAV by 1.6%

MT Newswires Live

Mar 26, 2025

Hearts and Minds Investments (ASX:HM1) said its revaluation of the holding value of Opthea (ASX: OPT) in its portfolio to AU$0.20 per share, will negatively impact its net asset value by about 1.6% or AU$0.056 per share, according to a Wednesday filing with the Australian bourse.

The revaluation takes into account the study results, as well as the potential for a "positive outcome" from the upcoming trial readout.

The company confirmed that it held a 2.4% stake in Opthea prior to the biopharmaceutical company's results of its study, the filing said.

Opthea said Monday that its Combination OPT-302 with Aflibercept (COAST) study in patients with age-related Macular Degeneration, failed to meet its primary endpoint and added there is significant doubt about its ability to continue as a going concern.

Shares of the company rose 1% in recent Wednesday trade.

Price (AUD): $3.05, Change: $+0.040, Percent Change: +1.33%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2522083015"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522083015\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2522083015?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-26 07:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522083015","market":"sh","top_or_hot":-1,"title":"HM1 Says Revaluation of Opthea's Holding Value to Negatively Impact NAV by 1.6%","media":"MT Newswires Live","content":"<html><body><p> Hearts and Minds Investments (ASX:HM1) said its revaluation of the holding value of Opthea (ASX: OPT) in its portfolio to AU$0.20 per share, will negatively impact its net asset value by about 1.6% or AU$0.056 per share, according to a Wednesday filing with the Australian bourse.</p><p>The revaluation takes into account the study results, as well as the potential for a \"positive outcome\" from the upcoming trial readout.</p><p>The company confirmed that it held a 2.4% stake in Opthea prior to the biopharmaceutical company's results of its study, the filing said.</p><p>Opthea said Monday that its Combination OPT-302 with Aflibercept (COAST) study in patients with age-related Macular Degeneration, failed to meet its primary endpoint and added there is significant doubt about its ability to continue as a going concern.</p><p>Shares of the company rose 1% in recent Wednesday trade.</p><p>Price (AUD): $3.05, Change: $+0.040, Percent Change: +1.33%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HM1 Says Revaluation of Opthea's Holding Value to Negatively Impact NAV by 1.6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHM1 Says Revaluation of Opthea's Holding Value to Negatively Impact NAV by 1.6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-26 07:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Hearts and Minds Investments (ASX:HM1) said its revaluation of the holding value of Opthea (ASX: OPT) in its portfolio to AU$0.20 per share, will negatively impact its net asset value by about 1.6% or AU$0.056 per share, according to a Wednesday filing with the Australian bourse.</p><p>The revaluation takes into account the study results, as well as the potential for a \"positive outcome\" from the upcoming trial readout.</p><p>The company confirmed that it held a 2.4% stake in Opthea prior to the biopharmaceutical company's results of its study, the filing said.</p><p>Opthea said Monday that its Combination OPT-302 with Aflibercept (COAST) study in patients with age-related Macular Degeneration, failed to meet its primary endpoint and added there is significant doubt about its ability to continue as a going concern.</p><p>Shares of the company rose 1% in recent Wednesday trade.</p><p>Price (AUD): $3.05, Change: $+0.040, Percent Change: +1.33%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HM1.AU","symbol_name":"HEARTS AND MINDS INVESTMENT","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2522083015","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522083015","pubTimestamp":1742946561,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hearts and Minds Investments  said its revaluation of the holding value of Opthea  in its portfolio to AU$0.20 per share, will negatively impact its net asset value by about 1.6% or AU$0.056 per share, according to a Wednesday filing with the Australian bourse.The revaluation takes into account the study results, as well as the potential for a \"positive outcome\" from the upcoming trial readout.The company confirmed that it held a 2.4% stake in Opthea prior to the biopharmaceutical company's results of its study, the filing said.Opthea said Monday that its Combination OPT-302 with Aflibercept  study in patients with age-related Macular Degeneration, failed to meet its primary endpoint and added there is significant doubt about its ability to continue as a going concern.Shares of the company rose 1% in recent Wednesday trade.Price : $3.05, Change: $+0.040, Percent Change: +1.33%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HM1.AU":"HEARTS AND MINDS INVESTMENT","BK4139":"生物科技","BK7067":"生物科技","BK7508":"医药生物股","OPT.AU":"OPTHEA LTD","NAV":"纳威司达"},"translate_title":"HM1表示Opthea持有价值重估将对资产净值产生1.6%的负面影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPT":1,"OPT.AU":1,"NAV":1,"HM1.AU":0.9},"content_text":"Hearts and Minds Investments (ASX:HM1) said its revaluation of the holding value of Opthea (ASX: OPT) in its portfolio to AU$0.20 per share, will negatively impact its net asset value by about 1.6% or AU$0.056 per share, according to a Wednesday filing with the Australian bourse.The revaluation takes into account the study results, as well as the potential for a \"positive outcome\" from the upcoming trial readout.The company confirmed that it held a 2.4% stake in Opthea prior to the biopharmaceutical company's results of its study, the filing said.Opthea said Monday that its Combination OPT-302 with Aflibercept (COAST) study in patients with age-related Macular Degeneration, failed to meet its primary endpoint and added there is significant doubt about its ability to continue as a going concern.Shares of the company rose 1% in recent Wednesday trade.Price (AUD): $3.05, Change: $+0.040, Percent Change: +1.33%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}